A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
Zhou C, Yang X, Yang B, Yan G, Dong X, Ding Y, Fan W, Li L, Yang D, Fang H, Ji C, Cheng H, Zhang S, Goh AH, Liu R, Gu X, Weng Z, Foley P, Sinclair R, Zhang J.
Zhou C, et al. Among authors: ji c.
J Am Acad Dermatol. 2023 Nov;89(5):911-919. doi: 10.1016/j.jaad.2023.02.063. Epub 2023 Apr 3.
J Am Acad Dermatol. 2023.
PMID: 37019385
Clinical Trial.